Use of a genomic test (MammaPrint™) in daily clinical practice to assist in risk stratification of young breast cancer patients

Archives of Gynecology and Obstetrics

Volumn 283, Issue 3, 2011, Pages 597-602

  Kunz, Georg ^a  

^a ST JOHANNES HOSPITAL   (Germany)

Author keywords

Breast cancer; Gene expression signature; MammaPrint; Meta analysis

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; ARTICLE; BREAST CANCER; CANCER PATIENT; CANCER RISK; CANCER SURVIVAL; CLINICAL PRACTICE; CONTROLLED CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; GENE EXPRESSION PROFILING; GENERAL HOSPITAL; GENETIC SCREENING; GERMANY; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; META ANALYSIS; OVERALL SURVIVAL; PRACTICE GUIDELINE; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; RISK ASSESSMENT;

ADULT; BREAST NEOPLASMS; CARCINOMA; FEMALE; GENE EXPRESSION PROFILING; GENOMICS; HUMANS; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; RISK; SENSITIVITY AND SPECIFICITY;

EID: 79951723483     PISSN: 09320067     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00404-010-1454-9     Document Type: Article

References (16)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687-1717
2. (1998) Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 352:930-942
3. Fan C, Oh DS, Wessels L, Weigelt B, Nuyten DS, Nobel AB, van't Veer LJ, Perou CM (2006) Concordance among gene- expression-based predictors for breast cancer. N Engl J Med 35:560-569
4. Sotiriou C, Pusztai L (2009) Gene-expression signatures in breast cancer. N Engl J Med 360:790-800
5. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Schreiber GJ, Peterse HL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van de Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH, Bernards R (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347:1999-2009
6. van't Veer LJ, Dai H, van de Vijer MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530-536
7. Buyse M, Loi S, van't Veer L, Viale G, Delorenzi M, Glas AM, d'Assignies MS, Bergh J, Lidereau R, Ellis P, Harris A, Bogaerts J, Therasse P, Floore A, Amakrane M, Piette F, Rutgers ET, Sotiriou C, Cardoso F, Piccart MJ (2006) Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst 98:1183-1192
8. Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thürlimann B, Senn HJ (2009) Threshold for therapies: highlights of the St. Gallen International expert consensus on the primary therapy of early breast cancer. Ann Oncol 20:1319-1329
9. Wittner BS, Sgroi DC, Ryan PD, Bruinsma TJ, Glas AM, Male A, Dahiya S, Habin K, Bernards R, Haber DA, Van't Veer LJ, Ramaswamy S (2008) Analysis of the MammaPrint breast cancer assay in a predominantly postmenopausal cohort. Clin Cancer Res 14:2988-2993
10. Mook S, Schmidt MK, Viale G, Pruneri G, Eekhout I, Floore A, Glas AM, Bogaerts J, Cardoso F, Piccart-Gebhart MJ, Rutgers ET, van't Veer L (2009) The 70-gene prognosis-signature predicts disease outcome in breast cancer patients with 1-3 positive lymph nodes in an independent validation study. Breast Cancer Res Treat 116:295-302
11. Ravdin PM, Siminoff LA, Davis GJ, Mercer MB, Hewlett J, Gerson N, Parker HL (2001) Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 19:980-991 (Pubitemid 32176272)
12. Olivotto IA, Bajdik CD, Ravdin PM, Speers CH, Coldman AJ, Norris BD, Davis GJ, Chia SK, Gelmon KA (2005) Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J Clin Oncol 23:2716-2725 (Pubitemid 46179461)
13. Goldhirsch A, Glick HJ, Gelber RD, Coates AS, Thürlimann B, Senn HJ (2005) Meeting highlights: international expert consensus on the primary therapy of early breast cancer. Ann Oncol 16:1569-1583 (Pubitemid 41511089)
14. Glas AM, Floore A, Delahaye LJMJ, Witteveen AT, Pover RCF, Bakx N, Lahti-Domenici JST, Bruinsma TJ, Warmoes MO, Bernards R, Wessels LFA, van't Veer LJ (2006) Converting a breast cancer microarray signature into a high throughput diagnostic test. BMC Genom 7:278
15. Bueno-de-Mesquita JM, van Harten WH, Retel VP, van't Veer LJ, van Dam FS, Karsenberg K, Douma KF, van Tinteren H, Peterse JL, Wesseling J, Wu TS, Atsma D, Rutgers EJ, Brink G, Floore AN, Glas AM, Roumen RM, Bellot FE, van Krimpen C, Rodenhuis S, van de Vijver MJ, Linn SC (2007) Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER). Lancet Oncol 8:1079-1087 (Pubitemid 350182954)
16. Mook S, Bonnefoi H, Pruneri G, Larsimont D, Jaskiewicz J, Sabadell MD, Macgrogan G, Van't Veer LJ, Cardoso F, Rutgers EJ (2009) Daily clinical practice of fresh tumour tissue freezing and gene expression profiling; logistics pilot study preceding the MINDACT trial. Eur J Cancer 45:1201-1208